Full TitleA Phase II trial of Pembrolizumab plus Olaparib for the Treatment of Patients with Peristent/Recurrent Endometrial Cancers
The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy and olaparib to treat people with endometrial cancer or endometrial carcinosarcoma that has continued to grow or came back despite treatment. Pembrolizumab works by boosting the ability of the immune system to detect and destroy cancer cells. Olaparib destroys cancer cells by preventing them from repairing damage to the genetic information that helps them survive and grow.
Both medications are used to treat other cancers; their use in this study is considered investigational. Pembrolizumab is given intravenously (by vein) and olaparib is taken orally (by mouth).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have serous endometrial cancer, endometrial carcinosarcoma, or endometrioid and/or undifferentiated carcinoma that came back or continued to grow despite treatment.
- Patients may not have previously received immunotherapy or a PARP inhibitor (such as olaparib, rucaparib, niraparib, or talozaporib).
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Maria Rubinstein at 646-888-6954.